For example, targeting most IGCTs with upregulated KIT/RAS/MAPK pathway and/or PI3K/AKT/mTOR pathway, designing inhibitors for these pathways may be a new idea for developing tumor-targeted drugs. This evidence concerns the gene AKT1 and neoplasm.